BioSpectrum the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

UK PM inspects Wockhardtâ??s fill finish production line

01 December 2020 | News

Wockhardt is focussed and committed to assisting in mitigating the worldwide impact of COVID-19



Wockhardt, the global pharmaceutical and biotechnology major headquartered in Mumbai, hosted a visit at its Wrexham facility in North Wales of the Prime Minister of the United Kingdom, Boris Johnson on 30th November.

The Prime Minister inspected the Wockhardt's fill-finish production line and was accompanied by local Wrexham Conservative MP Sarah Atherton.

The UK Government has reserved one fill and finish production line at Wockhardt UK for its exclusive use for 18 months in order to guarantee the supply of vaccines required to fight against COVID-19.

Wockhardt is a global pharmaceutical and biotech organization that brings affordable, high-quality medicines to market. As a global organization, Wockhardt is focussed and committed to assisting in mitigating the worldwide impact of COVID-19 and the collaboration with the UK Government to make vaccines available upholds its ongoing commitment to fight against such a pandemic of global human importance. In the UK, Wockhardt is one of the largest suppliers into the NHS for over 20 years, has had a presence in Wrexham for over two decades and employs over 400 people at its 612,000 square feet high-tech manufacturing facility.

Wockhardt's New Drug Discovery programme has focussed on the unmet need of making anti-bacterial drugs effective in mitigating untreatable superbugs. Wockhardt is the only company in the world that has received QIDP Status (Qualified Infectious Diseases Programme) from the US FDA for six anti-bacterial discovery programs – three of them are Gram-Negative and three Gram-Positive and are effective against untreatable "Superbugs". Wockhardt has a dedicated and experienced Drug Discovery team as part of its clinical research organization.